GLP-1 medications, metabolic testing, and physician-supervised weight loss — what the science says and how we apply it.

GLP-1 receptor agonists mimic an intestinal hormone that slows digestion, reduces appetite, and improves insulin response—producing 15-22% total body weight loss in trials when combined with lifestyle changes.
Semaglutide (Ozempic/Wegovy) delivers ~15% weight loss via GLP-1 receptor action, while tirzepatide (Mounjaro/Zepbound) achieves ~20–22% by targeting both GLP-1 and GIP receptors.